Lupin, Boehringer Ingelheim India to co-market diabetes drug Empagliflozin
Friday, October 14, 2016
Lupin Ltd - type 2 diabetes: Boehringer Ingelheim India and Lupin announce strategic co-marketing agreement. Lupin Ltd says will market, sell Empagliflozin under separate brand name Gibtulio.
Lupin Ltd says - Boehringer will continue to sell Empagliflozin under the brand name Jardiance via existing sales force and network.
Source : reuters.com
